Calculus pioneered tax efficient investing with the launch of the UK's first approved EIS Fund in 1999. The firm targets high growth private companies across sectors including technology, healthcare and entertainment.
Octopus Ventures led the Series B round, which will fund product development and international expansion.
"In a world in which volatility and complexity are increasing and the nature of work and talent are drastically changing, it is critical that organisations develop the capability and capacity to think and act differently when it comes to change and innovation"
The investment round was led by Volution, Calculus Capital and Gresham House Ventures to support business growth and product development.
"We are thrilled to be leading the current equity round for Rotageek"
The oversubscribed funding round includes participation from Mercia Asset Management, Calculus Capital, Downing Ventures, and BGF.
"We are delighted that our investors have emphatically and unanimously backed our vision to become leaders in next generation affinity reagents following the achievement of the key milestones we set together 18 months ago. We will continue to bring highly talented and experienced people to the business at all levels to accelerate our growth. This will be delivered by completing the industrialisation of our technology in targeted applications and bringing exciting new products to market to address unmet needs with high performance customer-centric solutions, which in turn will drive market adoption."
The Series A round was led by Calculus Capital and brings total funding to over £6m.
"In the last 18 months the world has seen the positive impact of video in recruitment as it helps to improve diversity, the candidate experience and time to hire."
Gresham House Ventures led the £7m Series A investment to support primary and secondary care expansion.
"This funding will help us keep pace with the product development we need to support cutting edge health technology across both primary and secondary care. NHS patients deserve an excellent digital experience when interacting with the health service and we now look forward to delivering the transformation needed."
